{"id":355370,"date":"2026-11-19T14:42:46","date_gmt":"2026-11-19T09:12:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355370"},"modified":"2026-11-19T14:42:46","modified_gmt":"2026-11-19T09:12:46","slug":"pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/","title":{"rendered":"3 Pharma Formulations Exporter, Cardiac Care Hospitals Chain and Innerwear Brand Stocks With a Strong Future Roadmap: Marksans Pharma, Narayana Hrudayalaya and Dollar Industries"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Marksans Pharma, Narayana Hrudayalaya and Dollar Industries: ROE of 11.3% to 17.8% and FY22 to FY26 revenue CAGR of 8.7% to 21.0%. Prices as of 18 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>export pharma, cardiac hospital and vest stocks<\/strong> to watch are <strong>Marksans Pharma<\/strong>, <strong>Narayana Hrudayalaya<\/strong> and <strong>Dollar Industries<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>11.3% to 17.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 8.7% to 21.0%. Narayana Hrudayalaya leads on both return on equity at 17.8% and revenue growth at 21.0% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Export pharma, cardiac hospital and vest stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Narayana Hrudayalaya and Dollar Industries cover a pharma formulations exporter, a cardiac care hospitals chain and an innerwear brand.<\/p>\n<p>This list covers three export pharma, cardiac hospital and vest stocks with complete current figures: Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#What_Are_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"What Are Export Pharma, Cardiac Hospital and Vest Stocks?\">What Are Export Pharma, Cardiac Hospital and Vest Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Export_Pharma_Cardiac_Hospital_and_Vest_Stocks_at_a_Glance\" title=\"Export Pharma, Cardiac Hospital and Vest Stocks at a Glance\">Export Pharma, Cardiac Hospital and Vest Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Why_Do_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Export Pharma, Cardiac Hospital and Vest Stocks Have a Strong Roadmap in India?\">Why Do Export Pharma, Cardiac Hospital and Vest Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Why_Marksans_Pharma_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"Why Marksans Pharma Features Among These Export Pharma, Cardiac Hospital and Vest Stocks\">Why Marksans Pharma Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Why_Narayana_Hrudayalaya_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"Why Narayana Hrudayalaya Features Among These Export Pharma, Cardiac Hospital and Vest Stocks\">Why Narayana Hrudayalaya Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Why_Dollar_Industries_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"Why Dollar Industries Features Among These Export Pharma, Cardiac Hospital and Vest Stocks\">Why Dollar Industries Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Marksans_Pharma_vs_Narayana_Hrudayalaya_vs_Dollar_Industries_on_Key_Financials\" title=\"Marksans Pharma vs Narayana Hrudayalaya vs Dollar Industries on Key Financials\">Marksans Pharma vs Narayana Hrudayalaya vs Dollar Industries on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Key_Risks_to_Check_Before_Investing_in_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"Key Risks to Check Before Investing in Export Pharma, Cardiac Hospital and Vest Stocks\">Key Risks to Check Before Investing in Export Pharma, Cardiac Hospital and Vest Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Final_Thoughts_on_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\" title=\"Final Thoughts on Export Pharma, Cardiac Hospital and Vest Stocks\">Final Thoughts on Export Pharma, Cardiac Hospital and Vest Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#What_are_export_pharma_cardiac_hospital_and_vest_stocks\" title=\"What are export pharma, cardiac hospital and vest stocks?\">What are export pharma, cardiac hospital and vest stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Which_export_pharma_cardiac_hospital_and_vest_stocks_are_covered_in_this_list\" title=\"Which export pharma, cardiac hospital and vest stocks are covered in this list?\">Which export pharma, cardiac hospital and vest stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Why_do_export_pharma_cardiac_hospital_and_vest_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do export pharma, cardiac hospital and vest stocks have a strong future roadmap in India?\">Why do export pharma, cardiac hospital and vest stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#How_has_Marksans_Pharma_performed_financially\" title=\"How has Marksans Pharma performed financially?\">How has Marksans Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#How_has_Narayana_Hrudayalaya_performed_financially\" title=\"How has Narayana Hrudayalaya performed financially?\">How has Narayana Hrudayalaya performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#How_has_Dollar_Industries_performed_financially\" title=\"How has Dollar Industries performed financially?\">How has Dollar Industries performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#What_risks_should_investors_check_before_buying_export_pharma_cardiac_hospital_and_vest_stocks\" title=\"What risks should investors check before buying export pharma, cardiac hospital and vest stocks?\">What risks should investors check before buying export pharma, cardiac hospital and vest stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand-stocks-roadmap-wetland-list\/#Is_this_list_of_export_pharma_cardiac_hospital_and_vest_stocks_investment_advice\" title=\"Is this list of export pharma, cardiac hospital and vest stocks investment advice?\">Is this list of export pharma, cardiac hospital and vest stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>What Are Export Pharma, Cardiac Hospital and Vest Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Export pharma, cardiac hospital and vest stocks<\/strong> are listed companies that make tablets, capsules and liquids for regulated overseas markets, run hospitals known for heart care and affordable surgery, and make and sell vests, briefs and thermal wear. Their earnings depend on export orders, patient numbers and apparel spending.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Export_Pharma_Cardiac_Hospital_and_Vest_Stocks_at_a_Glance\"><\/span><strong>Export Pharma, Cardiac Hospital and Vest Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\">Marksans Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">294.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,994<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.11<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/nh\/narayana-hrudayalaya-ltd-share-price-today\">Narayana Hrudayalaya<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,891.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35,603<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.29<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/dollar\/dollar-industries-ltd-share-price-today\">Dollar Industries<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">251.41<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,489<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.31<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a <strong>P\/E<\/strong> below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing export pharma, cardiac hospital and vest stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Export Pharma, Cardiac Hospital and Vest Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Export pharma, cardiac hospital and vest stocks have a strong roadmap in India because steady demand for affordable medicines abroad, wider access to quality surgery and steady spending on everyday apparel keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pharma exports.<\/strong> Overseas buyers need affordable medicines.<\/li>\n<li><strong>Cardiac hospitals.<\/strong> Families seek trusted surgeons.<\/li>\n<li><strong>Innerwear.<\/strong> Households replace basics regularly.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Marksans_Pharma_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>Why Marksans Pharma Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>export pharma, cardiac hospital and vest stocks<\/strong> on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.<\/p>\n<p>In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.<\/p>\n<p>Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a <strong>market capitalisation<\/strong> of Rs 12,994 crore. The stock trades at a <strong>P\/E<\/strong> of 24.9, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<p><strong>What to watch:<\/strong> Track export growth, new product approvals and plant utilisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Narayana_Hrudayalaya_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>Why Narayana Hrudayalaya Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the generic exporter, heart care chain and innerwear shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.<\/p>\n<p>The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P\/E of 43.6, below the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.<\/p>\n<p><strong>Roadmap:<\/strong> Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.<\/p>\n<p><strong>What to watch:<\/strong> Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dollar_Industries_Features_Among_These_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>Why Dollar Industries Features Among These Export Pharma, Cardiac Hospital and Vest Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Dollar Industries is a Kolkata-based innerwear and athleisure company that sells under brands such as Big Boss, Force NXT, Missy and Dollar Bigboss.<\/p>\n<p>Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P\/E of 13.3, below the industry P\/E of 35.2.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a wide distribution network across the country and has widened its range into women&#8217;s wear and athleisure. Brand extensions and a growing share of premium products support its plans.<\/p>\n<p><strong>What to watch:<\/strong> Track the growth in premium categories and the distributor network expansion.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_vs_Narayana_Hrudayalaya_vs_Dollar_Industries_on_Key_Financials\"><\/span><strong>Marksans Pharma vs Narayana Hrudayalaya vs Dollar Industries on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three export pharma, cardiac hospital and vest stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,533<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,033<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">420<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Narayana Hrudayalaya<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,996<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">810<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dollar Industries<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,349<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,885<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">107<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya combines the largest FY26 revenue at Rs 7,996 crore with the fastest revenue growth, a 21.0% compound annual rate. A useful habit with export pharma, cardiac hospital and vest stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Export Pharma, Cardiac Hospital and Vest Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>export pharma, cardiac hospital and vest stocks<\/strong>, the main points are: Long-term generic exporter, heart care chain and innerwear shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Currency moves.<\/strong> Export earnings move with the rupee.<\/li>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Consumer spending.<\/strong> Sales follow festivals, incomes and consumer mood.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter export pharma, cardiac hospital and vest stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Export_Pharma_Cardiac_Hospital_and_Vest_Stocks\"><\/span><strong>Final Thoughts on Export Pharma, Cardiac Hospital and Vest Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Export pharma, cardiac hospital and vest stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Narayana Hrudayalaya and Dollar Industries each have a clear plan to grow. Based on the 18 November 2026 close, Marksans Pharma trades at Rs 294.5, Narayana Hrudayalaya at Rs 1,891.3 and Dollar Industries at Rs 251.41. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these <strong>export pharma, cardiac hospital and vest stocks<\/strong> to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track export pharma, cardiac hospital and vest stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_export_pharma_cardiac_hospital_and_vest_stocks\"><\/span><strong>What are export pharma, cardiac hospital and vest stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Export pharma, cardiac hospital and vest stocks are listed companies that make tablets, capsules and liquids for regulated overseas markets, run hospitals known for heart care and affordable surgery, and make and sell vests, briefs and thermal wear. Their earnings depend on export orders, patient numbers and apparel spending. This list looks at three of them, Marksans Pharma, Narayana Hrudayalaya and Dollar Industries, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_export_pharma_cardiac_hospital_and_vest_stocks_are_covered_in_this_list\"><\/span><strong>Which export pharma, cardiac hospital and vest stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Based on the 18 November 2026 close, Marksans Pharma traded at Rs 294.5, Narayana Hrudayalaya at Rs 1,891.3 and Dollar Industries at Rs 251.41. Their return on equity ranges from <strong>11.3% to 17.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 8.7% to 21.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_export_pharma_cardiac_hospital_and_vest_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do export pharma, cardiac hospital and vest stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Export pharma, cardiac hospital and vest stocks have a strong roadmap in India because steady demand for affordable medicines abroad, wider access to quality surgery and steady spending on everyday apparel keep widening the market for these companies. The main drivers are as follows. Pharma exports. Overseas buyers need affordable medicines. Cardiac hospitals. Families seek trusted surgeons. Innerwear. Households replace basics regularly. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Marksans_Pharma_performed_financially\"><\/span><strong>How has Marksans Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Narayana_Hrudayalaya_performed_financially\"><\/span><strong>How has Narayana Hrudayalaya performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P\/E of 43.6, below the industry P\/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dollar_Industries_performed_financially\"><\/span><strong>How has Dollar Industries performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P\/E of 13.3, below the industry P\/E of 35.2. Looking ahead, the company has a wide distribution network across the country and has widened its range into women&#8217;s wear and athleisure. Brand extensions and a growing share of premium products support its plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_export_pharma_cardiac_hospital_and_vest_stocks\"><\/span><strong>What risks should investors check before buying export pharma, cardiac hospital and vest stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying <strong>export pharma, cardiac hospital and vest stocks<\/strong>. Currency moves. Export earnings move with the rupee. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_export_pharma_cardiac_hospital_and_vest_stocks_investment_advice\"><\/span><strong>Is this list of export pharma, cardiac hospital and vest stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are export pharma, cardiac hospital and vest stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Export pharma, cardiac hospital and vest stocks are listed companies that make tablets, capsules and liquids for regulated overseas markets, run hospitals known for heart care and affordable surgery, and make and sell vests, briefs and thermal wear. Their earnings depend on export orders, patient numbers and apparel spending. This list looks at three of them, Marksans Pharma, Narayana Hrudayalaya and Dollar Industries, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which export pharma, cardiac hospital and vest stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Based on the 18 November 2026 close, Marksans Pharma traded at Rs 294.5, Narayana Hrudayalaya at Rs 1,891.3 and Dollar Industries at Rs 251.41. Their return on equity ranges from 11.3% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do export pharma, cardiac hospital and vest stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Export pharma, cardiac hospital and vest stocks have a strong roadmap in India because steady demand for affordable medicines abroad, wider access to quality surgery and steady spending on everyday apparel keep widening the market for these companies. The main drivers are as follows. Pharma exports. Overseas buyers need affordable medicines. Cardiac hospitals. Families seek trusted surgeons. Innerwear. Households replace basics regularly. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Marksans Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Narayana Hrudayalaya performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P\/E of 43.6, below the industry P\/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.\"}},{\"@type\":\"Question\",\"name\":\"How has Dollar Industries performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P\/E of 13.3, below the industry P\/E of 35.2. Looking ahead, the company has a wide distribution network across the country and has widened its range into women's wear and athleisure. Brand extensions and a growing share of premium products support its plans.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying export pharma, cardiac hospital and vest stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying export pharma, cardiac hospital and vest stocks. Currency moves. Export earnings move with the rupee. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of export pharma, cardiac hospital and vest stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Export Pharma, Cardiac Hospital and Vest Stocks with a strong future roadmap: Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":355369,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,26320,26317,10107,26316,26318,26319,9051,7040,7564],"class_list":["post-355370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cardiac-care-hospitals-and-innerwear-stocks","tag-cardiac-hospital-and-vest-stocks","tag-dollar-industries","tag-export-pharma","tag-generic-exporter","tag-heart-care-chain-and-innerwear-shares","tag-marksans-pharma","tag-narayana-hrudayalaya","tag-pharma-formulations"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355369"],"rank_math_title":["Export Pharma, Cardiac Hospital and Vest Stocks"],"rank_math_description":["Compare 3 export pharma, cardiac hospital and vest stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 17 Nov 2026."],"rank_math_focus_keyword":["export pharma, cardiac hospital and vest stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-pharma-formulations-exporter-cardiac-care-hospitals-chain-and-innerwear-brand.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355370"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355370\/revisions"}],"predecessor-version":[{"id":355371,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355370\/revisions\/355371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355369"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}